欧盟批准了GSK的Nucala治疗高乙酸细胞的重症慢性肺炎,这是第一个每月使用的生物疗法,显著减少了发作和住院病例. The EU approved GSK’s Nucala for severe COPD with high eosinophils, the first monthly biologic therapy, showing major reduction in flare-ups and hospitalizations.

2026年2月8日,欧盟委员会批准了GSK的Nucala(mepolizumab),对象是没有控制的COPD和高血蛋白的成年人,标志着这个分组的首次每月生物治疗。 On February 8, 2026, the European Commission approved GSK’s Nucala (mepolizumab) for adults with uncontrolled COPD and elevated eosinophils, marking the first monthly biologic therapy for this subgroup. 批准之前,第3阶段的试验结果显示,突发事件减少了21%,需要紧急护理或住院治疗的严重事件减少了35%。 The approval followed positive phase 3 trial results showing a 21% reduction in flare-ups and a 35% drop in severe episodes requiring emergency care or hospitalization. GGSK的股票增长了0.8%,达到2 198便士,市场价值接近880亿英镑,比去年增加了49%。 GSK’s stock rose 0.8% to 2,198 pence, reaching a market value near £88 billion, with a 49% gain over the past year. 该公司的董事长在2月5日购买了2 500股股票。 The company’s chairman bought 2,500 shares on February 5. 投资者正在监测即将到来的红利日期——2月19日到期,记录日期为2月20日,支付日期为4月9日——而分析人员则等待关于采用处方和付款人偿还款的数据,因为生物学家在传统吸入器占主导地位的市场上面临障碍。 Investors are monitoring upcoming dividend dates—ex-dividend on February 19, record date February 20, payment April 9—while analysts await data on prescription adoption and payer reimbursement, as biologics face hurdles in a market dominated by traditional inhalers.